Panagiotis Karyofyllis1, Eftychia Demerouti2, Varvara Papadopoulou2, Vassilis Voudris2, Hiromi Matsubara3. 1. Division of Interventional Cardiology, Onassis Cardiac Surgery Center, Sygrou Ave 356, Kallithea, 17674, Athens, Greece. pakar768@yahoo.gr. 2. Division of Interventional Cardiology, Onassis Cardiac Surgery Center, Sygrou Ave 356, Kallithea, 17674, Athens, Greece. 3. Department of Clinical Science and Department of Cardiology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 7011192, Japan.
Abstract
PURPOSE OF REVIEW: Chronic thromboembolic pulmonary hypertension (CTEPH) is a major cause of precapillary pulmonary hypertension leading to right heart failure and death if left untreated. In addition to pulmonary endarterectomy, which is considered the standard of care, and specific drug therapy that is not however expected to offer relief from the mechanical component of the disease, the therapeutic options for CTEPH have expanded with the development of balloon pulmonary angioplasty (BPA). The purpose of this review is a better understanding and evaluation of BPA as a treatment option in CTEPH patients. RECENT FINDINGS: With the evolution of BPA almost all over the world, more centers outside Japan, which remains the leader for the technique, presented their results confirming the efficacy, safety, and feasibility of this procedure as a complementary strategy in the treatment algorithm of CTEPH. Summarizing, more data from all over the world confirm that BPA is a challenging but potentially effective intervention for the treatment of inoperable CTEPH patients. However, there is a need for standardization of the technique, and furthermore, large, international, multicenter randomized controlled trials comparing BPA with the other treatment modalities of CTEPH are imperative.
PURPOSE OF REVIEW: Chronic thromboembolic pulmonary hypertension (CTEPH) is a major cause of precapillary pulmonary hypertension leading to right heart failure and death if left untreated. In addition to pulmonary endarterectomy, which is considered the standard of care, and specific drug therapy that is not however expected to offer relief from the mechanical component of the disease, the therapeutic options for CTEPH have expanded with the development of balloon pulmonary angioplasty (BPA). The purpose of this review is a better understanding and evaluation of BPA as a treatment option in CTEPH patients. RECENT FINDINGS: With the evolution of BPA almost all over the world, more centers outside Japan, which remains the leader for the technique, presented their results confirming the efficacy, safety, and feasibility of this procedure as a complementary strategy in the treatment algorithm of CTEPH. Summarizing, more data from all over the world confirm that BPA is a challenging but potentially effective intervention for the treatment of inoperable CTEPH patients. However, there is a need for standardization of the technique, and furthermore, large, international, multicenter randomized controlled trials comparing BPA with the other treatment modalities of CTEPH are imperative.
Authors: Muhammad Shahzeb Khan; Emaan Amin; Muhammad Mustafa Memon; Naser Yamani; Tariq Jamal Siddiqi; Safi U Khan; Mohammad Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Rami Doukky; Raymond L Benza; Richard A Krasuski Journal: Int J Cardiol Date: 2019-02-23 Impact factor: 4.164
Authors: Robin Condliffe; David G Kiely; J Simon R Gibbs; Paul A Corris; Andrew J Peacock; David P Jenkins; Denise Hodgkins; Kim Goldsmith; Rodney J Hughes; Karen Sheares; Steven S L Tsui; Iain J Armstrong; Chantal Torpy; Rachel Crackett; Christopher M Carlin; Clare Das; J Gerry Coghlan; Joanna Pepke-Zaba Journal: Am J Respir Crit Care Med Date: 2008-02-21 Impact factor: 21.405
Authors: Xavier Jaïs; Andrea M D'Armini; Pavel Jansa; Adam Torbicki; Marion Delcroix; Hossein A Ghofrani; Marius M Hoeper; Irene M Lang; Eckhard Mayer; Joanna Pepke-Zaba; Loïc Perchenet; Adele Morganti; Gérald Simonneau; Lewis J Rubin Journal: J Am Coll Cardiol Date: 2008-12-16 Impact factor: 24.094